Lung Cancer
Volume 68, Issue 1 , Pages 78-83 , April 2010

Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer

  • Kazuhito Funai

      Affiliations

    • Division of Thoracic Surgery, Hamamatsu Medical Center, Hamamatsu, Japan
    • First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
    • Corresponding Author InformationCorresponding author at: Division of Thoracic Surgery, Hamamatsu Medical Center, 328, Tomitsuka, Naka, Hamamatsu, Shizuoka 432-8580, Japan. Tel.: +81 53 453 7111; fax: +81 53 451 2768.
    • ,
  • Kazuya Takamochi

      Affiliations

    • First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
    • ,
  • Toru Itaya

      Affiliations

    • First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
    • ,
  • Takahiro Mochizuki

      Affiliations

    • First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan
    • ,
  • Toru Nakamura

      Affiliations

    • Division of General Thoracic Surgery, Hamamatsu, Japan
    • ,
  • Futoru Toyoda

      Affiliations

    • Division of General Thoracic Surgery, Hamamatsu, Japan
    • ,
  • Kim Yong-Il

      Affiliations

    • Palliative Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan
    • ,
  • Kazuyoshi Sasaki

      Affiliations

    • Division of Thoracic Surgery, Hamamatsu Medical Center, Hamamatsu, Japan
    • ,
  • Shigeru Momiki

      Affiliations

    • Division of Thoracic Surgery, Hamamatsu Medical Center, Hamamatsu, Japan
    • ,
  • Tsuyoshi Takahashi

      Affiliations

    • Division of Cardiac and Thoracic Surgery, Fujieda Municipal General Hospital, Fujieda Japan
    • ,
  • Hiroshi Neyatani

      Affiliations

    • Division of Cardiac and Thoracic Surgery, Fujieda Municipal General Hospital, Fujieda Japan
    • ,
  • Kazuya Suzuki

      Affiliations

    • First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan

Received 31 March 2009 ,Revised 25 May 2009 ,Accepted 26 May 2009.

References 

  1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710–1717
  2. Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer. 2005;50:227–234
  3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909
  4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360
  5. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597
  6. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–727
  7. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3559
  8. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of 5 randomized trials including 4584 patients. J Clin Oncol. 2006;24:366S;[abstr. 7008]
  9. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26:5043–5051
  10. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996;2:521–530
  11. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol. 1995;22:72–79
  12. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 2005;47:69–80
  13. Vogl SE, Berenzweig M, Camacho F, Greenwald E, Kaplan BH. Efficacy study of intensive cis-platin therapy in advanced non-small cell bronchogenic carcinoma. Cancer. 1982;50:24–26
  14. Wilke H, Achterrath W, Schmoll HJ, Gunzer U, Preusser P, Lenaz L. Etoposide and split-dose cisplatin in small-cell lung cancer. Am J Clin Oncol. 1988;11:572–578
  15. Gandara DR, DeGregorio MW, Wold H, Wilbur BJ, Kohler M, Lawrence HJ, et al. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. J Clin Oncol. 1986;4:1787–1793
  16. Gandara DR, Wold H, Perez EA, Deisseroth AB, Doroshow J, Meyers F, et al. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst. 1989;81:790–794
  17. Kim JH, Lee DH, Shin HC, Kwon JH, Jung JY, Kim HJ, et al. A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2006;54:57–62
  18. Nagourney RA, Brewer CA, Radecki S, Kidder WA, Sommers BL, Evans SS, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol. 2003;88:35–39
  19. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol. 2000;18:2245–2249
  20. Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004;91:844–849
  21. Shepherd FA, Cormier Y, Burkes R, Evans WK, Goss G, Klimo P, et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol. 1997;24:S8-27–S8-30
  22. Berardi R, Porfiri E, Scartozzi M, Lippe P, Silva RR, Nacciarriti D, et al. Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology. 2003;65:198–203
  23. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317–323
  24. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol. 2005;23:4999–5006
  25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10
  26. Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol. 2004;22(Suppl.):621S;[abstr 7019]
  27. Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson DM, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of cancer and leukemia Group B protocol 9633. J Clin Oncol. 2006;24:365S;[abstr 7007]
  28. Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer. 2005;47:385–394

PII: S0169-5002(09)00320-1

doi: 10.1016/j.lungcan.2009.05.018

Lung Cancer
Volume 68, Issue 1 , Pages 78-83 , April 2010

Article Tools

* Image Usage & Resolution